| Literature DB >> 30922224 |
Zhen You1, Qinghe Zhang1, Changjun Liu2, Jiuzhou Song3, Ning Yang1, Ling Lian4.
Abstract
BACKGROUND: Marek's disease virus (MDV) is an oncogenic herpesvirus that can cause T-cell lymphomas in chicken. Long noncoding RNA (lncRNA) is strongly associated with various cancers and many other diseases. In chickens, lncRNAs have not been comprehensively identified. Here, we profiled mRNA and lncRNA repertoires in three groups of spleens from MDV-infected and non-infected chickens, including seven tumorous spleens (TS) from MDV-infected chickens, five spleens from the survivors (SS) without lesions after MDV infection, and five spleens from noninfected chickens (NS), to explore the underlying mechanism of host resistance in Marek's disease (MD).Entities:
Keywords: Chicken; Long noncoding RNA; MD resistance; Marek’s disease
Mesh:
Substances:
Year: 2019 PMID: 30922224 PMCID: PMC6438004 DOI: 10.1186/s12864-019-5625-1
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Overview of lncRNA identification in chicken spleen. a an overview of a comprehensive scheme for the identification of lncRNAs in chicken spleen. b the distributions of CSF scores of both coding and noncoding training data sets in CSF classifier. c receiver operating characteristic (ROC) analysis for training data sets to set a CSF score cut-off. The area under the curve (AUC) is 0.94 and the red square in line represents the optimal point with the best sensitivity and specificity
Information on the results of RNA-Seq data quality control and mapping
| Sample ID | Raw reads | Clean reads | Read length | Mapped reads | Concordantly mapped pairs | Concordant pair align rate (%) | Overall alignment rate (%) | Depth of coverage | Coverage |
|---|---|---|---|---|---|---|---|---|---|
| s17–1 | 108,038,362 | 107,236,056 | 150 | 99,071,070 | 47,355,310 | 88.32 | 92.39 | 71.44 | 99 M |
| s17–2 | 104,641,540 | 104,150,474 | 150 | 95,831,146 | 45,554,825 | 87.48 | 92.01 | 69.72 | 96 M |
| s14–5 | 104,552,356 | 104,012,122 | 150 | 96,002,848 | 45,706,899 | 87.89 | 92.3 | 59.93 | 96 M |
| s21–5 | 115,513,772 | 114,724,610 | 150 | 105,871,206 | 50,359,014 | 87.79 | 92.28 | 71.65 | 106 M |
| s12–1 | 121,782,278 | 121,124,168 | 150 | 111,411,790 | 53,080,305 | 87.65 | 91.98 | 72.78 | 111 M |
| s10–4 | 95,689,198 | 94,726,246 | 150 | 84,233,771 | 39,193,992 | 82.75 | 88.92 | 51.00 | 84 M |
| s13–2 | 102,265,142 | 100,720,338 | 150 | 89,382,799 | 41,657,926 | 82.72 | 88.74 | 59.45 | 89 M |
| s14–8 | 92,679,650 | 91,878,888 | 150 | 81,576,308 | 38,013,902 | 82.75 | 88.79 | 43.88 | 81 M |
| s16–2 | 100,808,994 | 100,163,884 | 150 | 92,596,205 | 44,222,526 | 88.3 | 92.44 | 60.53 | 93 M |
| s6–3 | 106,793,466 | 105,995,894 | 150 | 94,836,775 | 44,425,877 | 83.83 | 89.47 | 71.91 | 95 M |
| s7–2 | 117,484,294 | 116,319,496 | 150 | 98,372,279 | 45,819,569 | 78.78 | 84.57 | 66.10 | 98 M |
| s9–2 | 101,533,692 | 100,601,162 | 150 | 87,682,429 | 40,550,892 | 80.62 | 87.16 | 51.14 | 88 M |
| s24–11 | 108,771,468 | 108,057,900 | 150 | 100,009,407 | 47,516,011 | 87.95 | 92.55 | 54.06 | 100 M |
| s24–6 | 117,780,440 | 117,111,392 | 150 | 107,874,786 | 51,288,711 | 87.59 | 92.11 | 54.88 | 108 M |
| s24–7 | 125,499,128 | 124,725,286 | 150 | 114,662,567 | 54,498,218 | 87.39 | 91.93 | 72.64 | 115 M |
| s24–8 | 112,133,382 | 111,530,648 | 150 | 103,004,010 | 49,103,238 | 88.05 | 92.35 | 70.26 | 103 M |
| s24–9 | 100,700,518 | 100,087,486 | 150 | 92,311,210 | 43,884,783 | 87.69 | 92.23 | 55.25 | 92 M |
Fig. 2Genomic features and classification of putative lncRNAs. a classification of putative lncRNAs according to their genomic position in protein coding genes. b distribution of transcripts length. c distribution of exon number of lncRNAs and mRNAs. d cumulative distribution curve of gene expression levels (TPM). e cumulative distribution of conservation scores
Fig. 3Heatmaps of differentially expressed lncRNAs between the tumorous group and the survivors. a the expression levels of DE putative lncRNAs in each individual from the tumorous spleens and the spleens of survivors. b DE known lncRNAs in each individual from the tumorous spleens and the spleens of survivors
Fig. 4Co-expression network of DE protein coding genes and lncRNAs to predict the functional roles of candidate lncRNAs. a co-expression network visualization: nodes represent genes with the top 5% mutual correlation and each edge represents their close connection. b GO and KEGG pathway enrichment analysis for seven clusters with high phenotypic correlation. c sub-network of hub genes and candidate lncRNAs in cluster 1. This describes the relationship between candidate lncRNAs and hub protein coding genes
Fig. 5Quantitative PCR analysis of five candidate lncRNAs and IGF-I. * and ** respectively represent the significant difference in gene expression between two groups (* for P-value < 0.05 and ** for P-value < 0.01)
Fold change and adjusted P-value of partial specific intergroup DE genes and MD resistanc-associated genes reported previously
| Ensembl ID | Gene Name | TS vs. NS | TS vs. SS | ||
|---|---|---|---|---|---|
| Fold change | Padj | Fold change | Padj | ||
| ENSGALG00000000892 | IL10 | 6.70 | 7.77 × 10−18 | 3.30 | 1.80 × 10−3 |
| ENSGALG00000008267 | IL5RA | −3.03 | 1.90 × 10−5 | – | – |
| ENSGALG00000016288 | IL1RAPL1 | – | – | −3.44 | 1.29 × 10−6 |
| ENSGALG00000021113 | IL3 | 3.43 | 1.87 × 10−4 | – | – |
| ENSGALG00000006329 | IL9 | 4.62 | 2.17 × 10−2 | – | – |
| ENSGALG00000006801 | IL13 | 5.63 | 1.34 × 10−3 | – | – |
| ENSGALG00000009903 | IFNG | 2.32 | 3.43 × 10−4 | – | – |
| ENSGALG00000008666 | CTLA4 | 3.04 | 3.15 × 10−11 | – | – |
| ENSGALG00000014843 | TPD52L1 | – | – | −3.70 | 3.69 × 10− 2 |
| ENSGALG00000030115 | WISP1 | −2.35 | 6.24 × 10−4 | – | – |
| ENSGALG00000010152 | TSPAN8 | −2.68 | 4.69 × 10−4 | – | – |
| ENSGALG00000016590 | TLR7 | −3.15 | 4.58 × 10−7 | – | – |
| ENSGALG00000004096 | CHRNA7 | −2.42 | 9.81 × 10−6 | – | – |
| ENSGALG00000005750 | SWAP70 | −2.02 | 7.08 × 10−9 | – | – |
| ENSGALG00000015902 | CD8B | −2.90 | 8.98 × 10−6 | −3.37 | 6.70 × 10−5 |
| ENSGALG00000005194 | CD72 | −3.32 | 4.91 × 10−7 | −3.27 | 2.19 × 10−4 |
| ENSGALG00000000251 | CD79B | −2.69 | 4.97 × 10−6 | – | – |
| ENSGALG00000010854 | HDAC9 | −2.26 | 9.44 × 10−5 | – | – |
| ENSGALG00000000630 | HAS3 | 5.24 | 3.11 × 10−3 | – | – |
| ENSGALG00000006106 | TNFRSF6B | 10.88 | 1.11 × 10−15 | 2.78 | 2.22 × 10−2 |
| ENSGALG00000006346 | CXCL14 | 6.08 | 2.34 × 10−3 | – | – |
| ENSGALG00000041346 | CXCL12 | −2.14 | 7.89 × 10−5 | – | – |
| ENSGALG00000012755 | IGF-I | −4.60 | 2.35 × 10−7 | −4.15 | 6.40 × 10−5 |
| ENSGALG00000041204 | IGF2PB1 | 3.42 | 2.65 × 10−4 | – | – |
| ENSGALG00000036519 | CDC6 | 2.23 | 1.25 × 10−2 | – | – |
| ENSGALG00000034048 | BCL11A | – | – | −2.46 | 1.0 × 10−2 |
| ENSGALG00000021136 | VPREB3 | −3.84 | 4.05 × 10−5 | – | – |
| ENSGALG00000011355 | Wnt10A | – | – | 5.48 | 2.37 × 10−2 |
| ENSGALG00000036255 | Wnt7B | 2.90 | 2.82 × 10−2 | – | – |
| ENSGALG00000037494 | Wnt8C | 4.77 | 3.26 × 10−2 | – | – |
| ENSGALG00000000839 | Wnt11 | 4.48 | 1.72 × 10−3 | – | – |
| ENSGALG00000004401 | Wnt11B | 3.77 | 8.98 × 10−4 | – | – |
| ENSGALG00000039209 | WIF1 | 3.78 | 6 × 10−3 | ||
Abbreviation: TS the tumorous spleens, NS noninfected spleens, SS the spleens of survivors. Fold change greater than zero represents that genes expression level increase in the tumorous spleens. Fold change smaller than zero represents that genes expression level decrease in the tumorous spleens. “-” means no difference in expression level between compared groups
Detailed information on 17 total samples
| Group | Subgroup | Sample ID | Sex | Collection time point (dpi) |
|---|---|---|---|---|
| noninfected | – | s17–1 | Female | 43 |
| noninfected | – | s17–2 | Female | 43 |
| noninfected | – | s14–5 | Male | 40 |
| noninfected | – | s21–5 | Male | 49 |
| noninfected | – | s12–1 | Female | 37 |
| infected | tumorous | s10–4 | Female | 35 |
| infected | tumorous | s13–2 | Female | 38 |
| infected | tumorous | s14–8 | Female | 40 |
| infected | tumorous | s16–2 | Female | 42 |
| infected | tumorous | s6–3 | Female | 31 |
| infected | tumorous | s7–2 | Male | 32 |
| infected | tumorous | s9–2 | Female | 34 |
| infected | survivor | s24–11 | Female | 55 |
| infected | survivor | s24–6 | Female | 55 |
| infected | survivor | s24–7 | Female | 55 |
| infected | survivor | s24–8 | Female | 55 |
| infected | survivor | s24–9 | Male | 55 |